The Mayo test will directly compare the current standard test (CEA) to the Onko-Sure (New Test). Basically, when the FDA results were released years ago, doctors saw the Onko-Sure test as interesting and innovative but did not have real incentive to switch from the CEA test. This head to head test can help eliminate some variables when deciding which test is better on the whole. When they see that Onko-Sure outperforms CEA head to head then they will be more likely to consider it. How likely they are to consider it is dependent on how much PR RPC can get out to the masses about the benefits of their test over CEA.
This should be a bi-pronged attack: 1) The manner which was just recently discussed on this board, the "presentations" all to familiar to those who have been close to doctors and researchers where the drug/ diagnostic companies basically come to your lab/ office and buy you lunch or take you out to dinner etc (they are no longer allowed to give out merchandise by the way). 2) Advertisement directly to the patients or target demographic. Here you can can educate individuals at risk for CRC about their options and give them the results. When they begin requesting the Onko-Sure more frequently, then doctors are more likely to begin considering it or ordering it.
Again, this all depends on how much better Onko-Sure is than CEA as shown by the clinical trial.
